Free Trial
NASDAQ:BRNS

Barinthus Biotherapeutics Q1 2025 Earnings Report

Barinthus Biotherapeutics logo
$1.06 +0.08 (+7.61%)
Closing price 03:59 PM Eastern
Extended Trading
$1.06 0.00 (0.00%)
As of 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.34
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Barinthus Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Barinthus Biotherapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Barinthus Biotherapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Barinthus Biotherapeutics Earnings Headlines

Barinthus Biotherapeutics plc (BRNS) - Yahoo Finance
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Barinthus Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Barinthus Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your email.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics (NASDAQ:BRNS), Inc. (NASDAQ:BRNS) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel biologic therapies for autoimmune diseases and oncology. The company employs a proprietary antibody engineering platform to generate high-affinity molecules that selectively modulate immune responses, aiming to deliver targeted treatments with improved safety and efficacy. Its pipeline includes lead programs addressing inflammatory bowel disease and multiple sclerosis, alongside early-stage oncology candidates designed to harness immune checkpoints and cellular pathways for tumor suppression.

Founded in 2011 and headquartered in Cambridge, Massachusetts, Barinthus Biotherapeutics has built a research and development presence in North America and Europe, with collaborative agreements spanning academic institutions and biotech partners. The company has progressed its lead assets through preclinical and clinical development, leveraging a translational research approach to explore biomarkers and patient segmentation strategies. This global footprint allows Barinthus to access diverse patient populations and engage with regulatory authorities across key markets.

Barinthus’ leadership team comprises seasoned professionals with extensive experience in biologics development, regulatory affairs and commercial strategy. The executive bench includes industry veterans who have held senior roles at leading pharmaceutical and biotechnology firms, guiding programs from discovery through regulatory submission. Barinthus also benefits from a scientific advisory board that brings additional expertise in immunology, pharmacology and clinical trial design.

In addition to in-house development, Barinthus has established strategic collaborations with academic centers, contract research organizations and biotechnology alliances to accelerate its pipeline and optimize translational research. These partnerships provide access to specialized technologies, patient cohorts and manufacturing capabilities, facilitating efficient progression of lead candidates. As Barinthus advances its programs toward pivotal clinical milestones, the company remains committed to expanding its therapeutic portfolio and forging value-creating alliances across the global biopharmaceutical ecosystem.

View Barinthus Biotherapeutics Profile

More Earnings Resources from MarketBeat